GHENT, BELGIUM--(Marketwire - September 12, 2012) - Ablynx [Euronext Brussels: ABLX] announces
that it will be presenting at the UBS Global Life Sciences Conference,
which is
taking place from 19-20 September at the Grand Hyatt, New York.
The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses,
CEO and
Chairman of Ablynx on Thursday, 20 September at 02:00 p.m. EST / 08:00 p.m.
CET.
A live webcast of the event will be available via the following link.
Users are recommended to register at least 10 minutes ahead of the
event.
Shortly after the presentation, a replay of the webcast will be available
on the
Company's website www.ablynx.com.
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and
development
of Nanobodies®, a novel class of therapeutic proteins based on
single-domain
antibody fragments, for a range of serious human diseases,
including
inflammation, haematology, oncology and pulmonary disease. Today, the
Company
has approximately 25 programmes in the pipeline and seven Nanobodies
are at
clinical development stage. Ablynx has ongoing research
collaborations and
significant partnerships with major pharmaceutical companies,
including
Boehringer Ingelheim, Merck Serono and Novartis. The Company is
headquartered in
Ghent, Belgium. More information can be found on www.ablynx.com.
pdf version of the press release:
http://hugin.info/137912/R/1640289/528027.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1640289]
